IPOs: Biotech ChemoCentryx and specialty-pharma Xanodyne head for the public market
ChemoCentryx files for $58M IPO to fund autoimmune, inflammation drug — Mountain View, Calif.-based ChemoCentryx, a biotech focused on new small-molecule drugs that affect a class of biochemical signals known as chemokines, filed to raise $57.5 million in an initial offering. The company’s SEC filing is here.
Founded in 1997, ChemoCentryx believes drugs that interfere with chemokine signaling may be able to defuse runaway immune-system reactions that give rise to various autoimmune conditions, inflammation and even… Continue Reading